Press Releases :: Sonnet BioTherapeutics, Inc. (PURR)

Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination

Trading on The Nasdaq Capital Market under the ticker symbol “PURR”

Full Press Release Here

Apr 01, 2020 5:53pm EDT

Sonnet BioTherapeutics Holdings Announces Merger Closing

Feb 28, 2020 9:55am EST

Sonnet BioTherapeutics to Present at the 40th Annual Cowen Health Care Conference

Oct 22, 2019 9:28am EDT

Sonnet BioTherapeutics Selects Abzena as Clinical Stage Manufacturing Partner for its IL-12-FHAB cytokine-derived Therapeutic Candidate

Oct 10, 2019 4:05pm EDT

Chanticleer Holdings Announces Merger Agreement with Sonnet BioTherapeutics to Advance Pipeline of Novel Immune Therapeutics

Aug 12, 2019 7:47am EDT

Sonnet BioTherapeutics Announces Acquisition Agreement with Relief Therapeutics Holding SA for Atexakin Alpha (Interleukin-6)

Jul 17, 2018 10:26am EDT

Sonnet BioTherapeutics announces successful completion of Immuno-Oncology Discovery Program and Initiation of CMC Development of Platform Assets

Sep 25, 2017 11:36am EDT

Sonnet Biotherapeutics to present data on bispecific platform candidates at AACR and SITC Annual Meetings

1...
4
5
6
7
8
9
10
11
12
13